Redwood City, United States
Ashvattha Therapeutics, Inc., founded in 2015, is a pioneering force in the biotechnology and pharmaceutical sectors. Operating from its headquarters in the United States, the company is dedicated to transforming precision medicine through its proprietary hydroxyl dendrimer (HD) platform, exclusively licensed from Johns Hopkins University.
The core innovation lies in creating hydroxyl dendrimer therapeutics (HDTs), which enhance the targeting and efficacy of known small molecule drugs across a range of critical areas, including neurology, ophthalmology, hyperinflammatory diseases, and neuro-oncology. By delivering drugs with unprecedented precision, Ashvattha Therapeutics aims to redefine treatment standards and patient outcomes in these fields.
Recently, the company secured a substantial $50.00M Series B investment in January 2025 from seasoned investors Tribe Capital and Natural Capital, signaling strong market confidence and fueling its mission to revolutionize disease-targeted therapies.
